Financial Review: Atossa Genetics (NASDAQ:ATOS) and Bionik Laboratories (OTCMKTS:BNKL)

Atossa Genetics (NASDAQ:ATOS) and Bionik Laboratories (OTCMKTS:BNKL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Atossa Genetics and Bionik Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
Bionik Laboratories	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Atossa Genetics and Bionik Laboratories, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2	0	3	0	2.20
Bionik Laboratories	0	0	0	0	0.00

Atossa Genetics currently has a consensus target price of $20.33, indicating a potential upside of 784.06%. Given Atossa Genetics’ stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than Bionik Laboratories.

Earnings and Valuation

This table compares Atossa Genetics and Bionik Laboratories”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77 million	($3.21)	-0.72
Bionik Laboratories	N/A	N/A	N/A	($0.07)	N/A

Atossa Genetics is trading at a lower price-to-earnings ratio than Bionik Laboratories, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

12.7% of Atossa Genetics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 34.7% of Bionik Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

About Bionik Laboratories

Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Robots, which include a suite of robotic rehabilitation products; InMotion ARM, an evidence-based intelligent interactive rehabilitation technology that senses patient movements and limitations; InMotion ARM/HAND, which provides support for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion Connect platform that consists of a hardware device connected to the InMotion Robot, as well as a subscription to InMotion Connect Pulse. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts.